Table 1.
Pretreatment characteristics of CML-CP patients treated with dasatinib and nilotinib after PS matching.
| Dasatinib (N = 87) | Nilotinib (N = 87) | P value | |
|---|---|---|---|
| Median age | 49 (19-79) | 47 (17-80) | 0.87 |
| Age ≥ 65 | 6 (7) | 6 (7) | 1.00 |
| Female | 37 (43) | 38 (44) | 0.85 |
| Sokal Score Group | |||
| Low | 69 (79) | 66 (76) | 0.78 |
| Intermediate | 14 (16) | 15 (17) | |
| High | 4 (5) | 6 (7) | |
| WBC, ×103/μL | 23.9 (0.8-193.0) | 39.8 (1.4-342.5) | 0.51 |
| HGB, g/dL | 11.9 (8.8-16.2) | 12.4 (8.9-15.8) | 0.65 |
| PLT, ×103/μL | 337 (86-1906) | 322 (73-1356) | 0.92 |
| BM blast % | 2 (0-6) | 2 (0-7) | 0.53 |
| BM blast ≥ 5 % | 3 (4) | 3 (4) | 1.00 |
| LDH, IU/L | 894 (393-3648) | 1097 (252-3467) | 0.37 |
| CRE, mg/dL | 0.9 (0.6-1.3) | 0.9 (0.6-1.3) | 0.27 |
| TBIL, mg/dL | 0.4 (0.2-3.4) | 0.4 (0.1-1.3) | 0.54 |
| ALB, mg/dL | 4.4 (3.7-5.5) | 4.4 (3.3-5.5) | 0.79 |
| AST, IU/L | 32 (14-121) | 36 (12-101) | 0.65 |
| ALT, IU/L | 25 (12-154) | 27 (11-84) | 0.94 |
| BCR-ABL1, IS | 14.1 (0.04-35.4) | 14.1 (0.01-35.4) | 0.68 |
| BCR-ABL1 type | |||
| b2a2 | 32 (37) | 34 (39) | 0.74 |
| b3a2 | 32 (37) | 37 (43) | |
| b3a3 | 1 (1) | 0 (0) | |
| b2a2 + b3a2 | 21 (24) | 15 (17) | |
| e1a2 | 1 (1) | 1 (1) | |
|
Previous use of
imatinib (<30 days) |
17 (19) | 14 (16) | 0.55 |
NOTE: The numbers are shown in either No. (%) or median (range) style; WBC, white blood cell count; HGB, hemoglobin; PLT, platelet count; BM, bone marrow; LDH, lactate dehydrogenase; CRE, creatinine; TBIL, total bilirubin; ALB, albumin; AST, aspartate transaminase; ALT, alanine transaminase; IS; international scale.